phrykt

Ocular Therapeutix, Inc (OCUL): who owns it and who trades it

As of Nov 16, 2026, OCUL insiders reported 29 open-market sales worth $3.3M and 1 purchase worth $461K in the last 12 months, with 93% of the sale value made under pre-set 10b5-1 plans. The largest seller was Pravin Dugel (Director), with $1.9M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ocular Therapeutix

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns OCUL

262 funds and institutions reported OCUL shares worth $2B at the end of Q2 2026, about 95% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) 95%Everyone else 5%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
Deep Track Capital, LP9.0%
BlackRock, Inc.8.8%
Avoro Capital Advisors LLC5.7%
Summer Road LLC5.6%
Venrock Adviser, LLC4.7%
Vanguard Capital Management LLC4.0%
T. Rowe Price Associates3.5%
Logos Global Management LP2.4%
State Street Corp2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)32.84M15.00%$323M+1%
Deep Track Capital, LP19.69M8.99%$193MNo change
BlackRock, Inc.19.38M8.85%$190M+20%
Avoro Capital Advisors LLC12.54M5.73%$123M+2%
Summer Road LLC12.21M5.58%$120M+3%
Venrock Adviser, LLC10.35M4.73%$102MNo change
Vanguard Capital Management LLC8.83M4.03%$86.7M+1%
T. Rowe Price Associates7.62M3.48%$74.9M+29%
Logos Global Management LP5.30M2.42%$52M+38%
State Street Corp5.23M2.39%$51.4M+11%
Geode Capital Management, LLC5.02M2.29%$49.3M+11%
Point72 Asset Management, L.P.3.29M1.50%$32.3M-41%
Dimensional Fund Advisors LP2.78M1.27%$27.3M+328%
Deltec Asset Management LLC2.48M1.13%$24.3M+6%
Balyasny Asset Management L.P.2.27M1.04%$22.3M-16%
Octagon Capital Advisors LP2.08M0.95%$20.4M-34%
Vanguard Portfolio Management LLC1.97M0.90%$19.4M+24%
Northern Trust Corp1.80M0.82%$17.7M+18%
Goldman Sachs Group Inc1.76M0.80%$17.3M+59%
Nuveen, LLC1.70M0.78%$16.7M+313%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, OCUL insiders reported $461K of open-market purchases and $3.3M of sales. 93% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$461K
1 trades, 1 people
Sales, 12 months
$3.3M
29 trades, 8 people
Sales under a 10b5-1 plan
93%
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 9, 2026

Purchases and sales by month

$1.8M$1.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026Namrata SarojChief Business OfficerSale plan35,370$6.55$232KForm 4
Oct 8, 2026Todd AndermanChief Legal OfficerSale plan11,984$7.29$87.4KForm 4
Oct 2, 2026Jeffrey S. HeierChief Scientific OfficerSale plan10,869$7.05$76.6KForm 4
Oct 2, 2026Peter KaiserChief Development OfficeSale plan9,990$7.05$70.4KForm 4
Aug 31, 2026Donald NotmanChief Operating OfficerSale1,099$10.24$11.3KForm 4
Aug 24, 2026Peter KaiserChief Development OfficeSale plan3,035$10.77$32.7KForm 4
Aug 24, 2026Sanjay NayakChief Strategy OfficerSale plan1,897$10.78$20.4KForm 4
Aug 24, 2026Jeffrey S. HeierChief Scientific OfficerSale plan3,296$10.78$35.5KForm 4
Aug 24, 2026Pravin DugelDirectorSale plan21,649$10.77$233KForm 4
Jun 3, 2026Nadia WaheedChief Medical OfficerSale plan14,828$8.27$123KForm 4
May 26, 2026Pravin DugelDirectorSale plan21,156$8.20$173KForm 4
May 26, 2026Peter KaiserChief Development OfficeSale plan2,967$8.20$24.3KForm 4
May 26, 2026Jeffrey S. HeierChief Scientific OfficerSale plan3,018$8.20$24.7KForm 4
May 26, 2026Sanjay NayakChief Strategy OfficerSale plan1,858$8.20$15.2KForm 4
Feb 23, 2026Pravin DugelDirectorSale plan20,056$8.28$166KForm 4
Feb 23, 2026Peter KaiserChief Development OfficeSale plan2,810$8.28$23.3KForm 4
Feb 23, 2026Jeffrey S. HeierChief Scientific OfficerSale plan3,057$8.28$25.3KForm 4
Feb 23, 2026Sanjay NayakChief Strategy OfficerSale plan1,759$8.28$14.6KForm 4
Feb 20, 2026Nadia WaheedChief Medical OfficerSale plan3,510$7.74$27.2KForm 4
Feb 20, 2026Richard L Md LindstromDirectorPurchase60,229$7.66$461KForm 4
Feb 12, 2026Donald NotmanChief Operating OfficerSale11,446$9.04$103KForm 4
Feb 12, 2026Sanjay NayakChief Strategy OfficerSale plan10,348$9.04$93.5KForm 4
Feb 12, 2026Pravin DugelDirectorSale plan124,882$9.04$1.1MForm 4
Feb 12, 2026Nadia WaheedChief Medical OfficerSale plan7,863$9.04$71.1KForm 4
Feb 4, 2026Donald NotmanChief Operating OfficerSale6,035$8.54$51.5KForm 4
Feb 2, 2026Donald NotmanChief Operating OfficerSale5,455$9.14$49.9KForm 4
Nov 24, 2025Sanjay NayakChief Strategy OfficerSale plan1,878$12.04$22.6KForm 4
Nov 24, 2025Pravin DugelDirectorSale plan19,530$12.04$235KForm 4
Nov 24, 2025Peter KaiserChief Development OfficeSale plan3,007$12.02$36.1KForm 4
Nov 24, 2025Jeffrey S. HeierChief Scientific OfficerSale plan3,469$12.04$41.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Pravin DugelSee Remarks, Director–$1.9MAug 24, 2026
Richard L Md LindstromDirector$461K–Feb 20, 2026
Namrata SarojChief Business Officer–$232KNov 5, 2026
Nadia WaheedChief Medical Officer–$221KJun 3, 2026
Donald NotmanChief Operating Officer–$216KAug 31, 2026
Jeffrey S. HeierChief Scientific Officer–$204KOct 2, 2026
Peter KaiserChief Development Officer–$187KOct 2, 2026
Sanjay NayakChief Strategy Officer–$166KAug 24, 2026
Todd AndermanChief Legal Officer–$87.4KOct 8, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

OCUL short interest

High short interest. 13.2% of OCUL shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 17%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 29.00M OCUL shares were sold short, 13.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 10.1 trading days (days to cover).

Shares short, % of all shares

13.2%May 15Oct 3014.0%

Days to cover

10.1May 15Oct 3015.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202629.00M13.20%+1%2.86M10.1
Oct 15, 202628.76M13.10%-2%3.55M8.1
Sep 30, 202629.41M13.39%-2%4.06M7.2
Sep 15, 202629.93M13.63%+7%2.11M14.2
Aug 31, 202628.06M12.77%-2%3.13M9.0
Aug 14, 202628.52M12.98%+7%2.25M12.7
Jul 31, 202626.74M12.17%-1%1.98M13.5
Jul 15, 202627.03M12.34%+1%2.07M13.1
Jun 30, 202626.70M12.19%+1%4.07M6.6
Jun 15, 202626.46M12.08%+5%2.23M11.8
May 29, 202625.09M11.46%+1%2.77M9.0
May 15, 202624.78M11.32%-0%2.92M8.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Ocular Therapeutix company events

Ocular Therapeutix filed 11 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026LeadershipThe Board of Directors of Ocular Therapeutix, Inc., following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Riad Sherif, M.D., to serve as a member of the Board, effective immediately. Filing
  2. Nov 9, 2026ResultsReleased financial results. Filing
  3. Oct 16, 2026LeadershipSanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc., notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company. Filing
  4. Aug 3, 2026ResultsReleased financial results. Filing
  5. Jun 12, 2026LeadershipOcular Therapeutix, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  6. May 5, 2026ResultsReleased financial results. Filing
  7. Feb 27, 2026AnnouncementShared information with investors. Filing
  8. Feb 5, 2026ResultsReleased financial results. Filing
  9. Jan 23, 2026LeadershipDonald Notman, Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer) of Ocular Therapeutix, Inc., is taking a temporary medical leave of absence from the Company. Filing
  10. Dec 18, 2025AnnouncementAs the Company prepares for database lock for its SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration, the Company is entering a quiet period beginning December 20, 2025. Filing
  11. Dec 5, 2025AnnouncementThe U.S. Food and Drug Administration has historically required two adequate and well-controlled clinical trials to demonstrate the safety and efficacy of ophthalmic product candidates, in particular for larger indications such as wet age-related macular degeneration. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ocular Therapeutix financials

Famous investors that hold OCUL

3 of the 50 well-known investors we track reported holding OCUL in their latest 13F filing. The largest position is Jim Simons's, worth $4.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026540,900$4.1M0.0%+43%
Ken Griffin · Citadel AdvisorsQ3 2026441,769$3.4M0.0%+42%
Steve Cohen · Point72 Asset ManagementQ3 2026283,555$2.2M0.0%-91%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Ocular Therapeutix, Inc (OCUL) stock

Who owns the most OCUL stock?

The largest reported owner of Ocular Therapeutix, Inc (OCUL) is FMR LLC (Fidelity), with 15.0% of the company. In total, 262 funds and institutions reported holding OCUL at the end of Q2 2026, together about 95% of the shares. See the largest owners.

Are OCUL insiders buying or selling?

In the last 12 months, OCUL insiders reported 1 open-market purchase worth $461K and 29 sales worth $3.3M. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in OCUL?

As of Oct 30, 2026, 29.00M OCUL shares were sold short, 13.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 10.1 trading days (days to cover). See the history.

Which famous investors hold OCUL?

3 of the 50 well-known investors we track reported OCUL in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $4.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.